Amylyx Pharmaceuticals clinical trials we track

Check company identity source

Phase 3 3 trials

TrialDrugs studiedStatusPrimary completion
Avexitide for Treatment of Post-Bariatric HypoglycemiaNCT06747468AvexitideActive not recruiting2026-07-08Actual
Extension Study Evaluating The Safety And Tolerability of AMX0035NCT05619783AMX0035Completed2024-10-16Actual
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis TreatmentNCT05021536AMX0035Unknown2024-01-19Actual

Phase 2 / 3 1 trial

TrialDrugs studiedStatusPrimary completion
AMX0035 and Progressive Supranuclear PalsyNCT06122662AMX0035Completed2025-09-30Actual

Phase 2 4 trials

TrialDrugs studiedStatusPrimary completion
AMX0035 in Adult Patients With Wolfram SyndromeNCT05676034AMX0035Active not recruiting2024-07-23Actual
Open Label Extension Study of AMX0035 in Patients With ALSNCT03488524AMX0035Completed2021-03-01Actual
Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's DiseaseNCT03533257AMX0035Completed2020-10-22Actual
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT03127514AMX0035Completed2019-09-25Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2022-09MonthAMX0035Amylyx Pharmaceuticals Inc. · AMLXCompany-disclosed PDUFA goal dateAnnounced review targettreatment of ALSOpen original source
Read source excerpt

the FDA originally set the PDUFA date for AMX0035 for the treatment of ALS, for June 29, 2022, and then extended the review timeline for our NDA to September 2022

First seen: 08 Nov 2026 · Evidence last checked: 08 Nov 2026

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters
AMX0035 and Progressive Supranuclear Palsy

NCT06122662 · Amylyx Pharmaceuticals Inc.

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 110 participants (planned). After: 139 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 1 Apr 2026. After: 30 Sep 2025.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source
AMX0035 in Adult Patients With Wolfram Syndrome

NCT05676034 · Amylyx Pharmaceuticals Inc.

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To evaluate the effect of AMX0035 on residual beta-cell function by monitoring C-peptide levels during a 0-240 minutes mixed-meal tolerance test (MMTT) Measure: To assess the safety and tolerability of AMX0035 administered orally for up to 144 weeks in adult participants with Wolfram syndrome. After: Measure: To evaluate the effect of AMX0035 on residual beta-cell function by monitoring C-peptide levels during a 0-240 minutes mixed-meal tolerance test (MMTT) Measure: To assess the safety and tolerability of AMX0035 administered orally for up to 208 weeks in adult participants with Wolfram syndrome.

Check registry source